Have a primary diagnosis of B cell non-Hodgkin lymphoma
\- Histologically confirmed: Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B Cell Lymphoma (PMBCL), Transformation Follicular Lymphoma (TFL), High grade B-cell Lymphoma (HGBCL), Mantle cell Lymphoma (MANT), Burkitt Lymphoma (BURK), Lymphoblastic Lymphoma
Chemotherapy-refractory disease, defined as one of more of the following No response to last line of therapy OR Refractory post-autologous stem cell transplant (ASCT)
Individuals must have received adequate prior therapy including at a minimum:
anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20-negative and an anthracycline containing chemotherapy regimen for individual with transformed FL must have chemorefractory disease after transformation to DLBCL.
No active infection of HIV, HTLV and Syphilis
Adequate renal function
Adequate hepatic function
Adequate cardiac function
Adequate venous access for apheresis, and no other contraindications for leukapheresis
Voluntary informed consent is given.
You may not be if
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
Received allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)
Body weight less than 30 kg
Pregnant or lactating women.
Uncontrolled active infection.
History of hepatitis B or hepatitis C infection.
Previously treatment with any gene therapy products or cell therapy product in past 28 days.
HIV infection.
Lymphoma with central nervous system (CNS) involvement
Have autoimmune disorders
Have active infection or inflammatory disorders
Prescreening test results in expansion rate less than 5 folds
An allergy to gentamycin and/or streptomycin
Clareo Health | Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma
